Fortis Life Sciences acquires Abcore, a leader in nanobody technologies

Fortis Life Sciences has acquired Abcore, a San Diego, California, USA based antibody discovery platform specializing in nanobody technology. With the addition of Abcore, Fortis extends its capabilities into the antibody discovery market serving biopharma customers developing antibody and nanobody-based therapeutics.

Abcore is a powerful addition to the Fortis portfolio and deepens our antibody product and service capabilities. We are particularly optimistic about the potential of nanobody technologies in therapeutic and diagnostic applications. Our acquisition of Abcore aligns perfectly with Fortis’ goal of partnering with and investing in world-class life sciences companies seeking a strategic growth partner.”

Brian Kim, Chief Executive Officer, Fortis, Remarked on the Partnership

“We are excited about accelerating Abcore’s growth as part of the Fortis family,” added David Barraclough, Chief Executive Officer of Abcore. “Fortis shares our commitment to scientific discovery, innovation, and customer service and is the ideal partner for Abcore as we expand our technical capabilities and bring new products and services to market.”

Our partnership with Fortis will provide Abcore with the commercial and operational infrastructure necessary for us to focus on developing high-quality products and better serving our customers.”

Jennifer Johnson, President of Abcore

Pivotal Scientific Ltd. acted as the exclusive corporate advisor to Abcore.